<DOC>
	<DOCNO>NCT01605773</DOCNO>
	<brief_summary>This trial conduct United States America ( USA ) . The aim trial compare effect repaglinide postprandial lipemia subject type 2 diabetes .</brief_summary>
	<brief_title>Effect Repaglinide Postprandial Lipemia Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Repaglinide</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>Newly diagnose patient type 2 diabetes currently treat diet exercise alone ( HbA1c 10 % ) Subjects type 2 diabetes treat sulphonylurea ( HbA1c 8.5 % ) Males nonpregnant , nonlactating female Subjects normal renal function Type 1 specific cause diabetes Marked symptomatic diabetes Uncontrolled treated/untreated hypertension Known suspect allergy trial product relate product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>